NCT05184179

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

A Multi-center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab. for Patients With Hypertension and Dyslipidemia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 5,450 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks).

Detailed description

The study will start after investigator determines the administration of Olomax tablets based on the investigator's judgement and obtaining informed consent from the subject during subject's daily visit. The dose of the Olomax tablet for each subject will be determined based on efficacy and drug resistance according to the subject's previous drug administration. Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks). Efficacy of Olomax tablets will be evaluated based on the data collected from more than 24 weeks to 48 weeks(+8 weeks) from the baseline visit. Safety of Olomax tablets will be evaluated based on the adverse events collected during the study peroid.

Conditions

• Hypertension
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Olmesartan Medoxomil	Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca

Timeline

• Start date: 2019-12-01
• Primary completion: 2022-08-16
• Completion: 2022-08-16
• First posted: 2022-01-11
• Last updated: 2024-07-01

Locations

1 site across 1 country: South Korea